Response to the letter 'Minimization: not all it's cracked up to be' by Berger.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Works matching IS 17407745 AND DT 2011 AND VI 8 AND IP 4
Results: 21
1
2
Minimization: not all it's cracked up to be.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
3
Clinician-trialist rounds: 5. Cointervention bias - how to diagnose it in their trial and prevent it in yours.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
4
A tale of five opinions (at least)
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
5
Author contact information.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 549, doi. 10.1177/1740774511413038
- Publication type:
- Article
6
Abstracts.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 445, doi. 10.1177/1740774511413037
- Publication type:
- Article
7
Author Response.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 430, doi. 10.1177/1740774511411323
- By:
- Publication type:
- Article
8
Translating study results to labeling.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 427, doi. 10.1177/1740774511411322
- By:
- Publication type:
- Article
9
A tale of five opinions (at least).
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 423, doi. 10.1177/1740774511411321
- By:
- Publication type:
- Article
10
Clinician-trialist rounds: 5. Cointervention bias – how to diagnose it in their trial and prevent it in yours.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 440, doi. 10.1177/1740774511410995
- By:
- Publication type:
- Article
11
Some essential considerations in the design and conduct of non-inferiority trials.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 432, doi. 10.1177/1740774511410994
- By:
- Publication type:
- Article
12
Incorporating lower grade toxicity information into dose finding designs.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 370, doi. 10.1177/1740774511410732
- By:
- Publication type:
- Article
13
Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 398, doi. 10.1177/1740774511410582
- By:
- Publication type:
- Article
14
Regulatory divergence.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 425, doi. 10.1177/1740774511410456
- By:
- Publication type:
- Article
15
Response to the letter ‘Minimization: not all it’s cracked up to be’ by Berger.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 444, doi. 10.1177/1740774511410253
- By:
- Publication type:
- Article
16
Minimization: not all it’s cracked up to be.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 443, doi. 10.1177/1740774511409769
- By:
- Publication type:
- Article
17
Equipoise should be amended, not abandoned.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 408, doi. 10.1177/1740774511409600
- By:
- Publication type:
- Article
18
Dose-finding design for multi-drug combinations.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 380, doi. 10.1177/1740774511408748
- By:
- Publication type:
- Article
19
A tale of three labels: translating the JUPITER trial data into regulatory claims.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 417, doi. 10.1177/1740774511407939
- By:
- Publication type:
- Article
20
The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 361, doi. 10.1177/1740774511407533
- By:
- Publication type:
- Article
21
Confounding due to changing background risk in adaptively randomized trials.
- Published in:
- Clinical Trials, 2011, v. 8, n. 4, p. 390, doi. 10.1177/1740774511406950
- By:
- Publication type:
- Article